Bischloroanthrabenzoxocinone  (Synonyms: (-)-BABX)

Bischloroanthrabenzoxocinone is a potent Type II fatty acid synthesis (FASII) inhibitor. Bischloroanthrabenzoxocinone inhibits fatty acid synthesis. Bischloroanthrabenzoxocinone shows antibacterial activities and inhibits phospholipid, DNA, RNA, protein, and cell wall synthesis^[1].

Bischloroanthrabenzoxocinone (0.01-333 µg/mL) inhibits fatty acid synthesis with the IC₅₀ values of 11.4, 35.3 µg/mL for Staphylococcus aureus and Escherichia coli, respectively^[1].
Bischloroanthrabenzoxocinone (0-250 µg/mL) shows antibacterial activities with MIC values of 0.2, >250 µg/mL for Staphylococcus aureus and wild type Escherichia coli, respectively^[1].
Ischloroanthrabenzoxocinone inhibits phospholipid synthesis with an IC₅₀ value of 0.21 μg/ml, and it also inhibits DNA, RNA, protein, and cell wall syntheses in Staphylococcus aureus and Escherichia coli^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

543.39

C₂₈H₂₄Cl₂O₇

866022-28-8

OC1=C(C(C2)=CC(C(C)(C3=C4Cl)C)=C1C(C3=C(C(Cl)=C4O)O)=O)[C@](O[C@@]25C)([H])C(C(O5)=CC(OC)=C6)=C6C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kodali S, et al. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem. 2005 Jan 14;280(2):1669-77.  [Content Brief]